MarketPulse

EP-104GI

3 articles
GlobeNewswire Inc.GlobeNewswire Inc.··Na

Eupraxia Raises $63.2M, Eyes 2028 as Cash-Runway Extends Despite Rising Losses

Eupraxia Pharmaceuticals closed $63.2M offering, boosting cash to $80.5M with runway through H2 2028. Q4 losses doubled to $16.7M amid clinical progress in eosinophilic esophagitis treatment.
EPRXpublic offeringdrug delivery
BenzingaBenzinga··Globe Newswire

Eupraxia Pharmaceuticals Completes $63.2M Offering to Fund GI Disease Pipeline

Eupraxia Pharmaceuticals raises $63.2M to advance its GI disease pipeline, including EP-104GI trials for eosinophilic esophagitis and other gastrointestinal indications.
EPRXclinical trialspublic offering
GlobeNewswire Inc.GlobeNewswire Inc.··Na

Eupraxia Pharmaceuticals Raises $55M Through Public Offering to Fund GI Pipeline

Eupraxia Pharmaceuticals raises $55M via public offering to advance EP-104GI for eosinophilic esophagitis through Phase 2/3 development and expand GI pipeline.
EPRXclinical trialspublic offering